Impact of Remote Monitoring on Long-Term Prognosis in Heart Failure Patients in a Real-World Cohort: Results From All-Comers COMMIT-HF Trial

2017 ◽  
Vol 28 (4) ◽  
pp. 425-431 ◽  
Author(s):  
ANNA KUREK ◽  
MATEUSZ TAJSTRA ◽  
ELZBIETA GADULA-GACEK ◽  
PIOTR BUCHTA ◽  
MICHAL SKRZYPEK ◽  
...  
Keyword(s):  
Heart Failure ◽  
Real World ◽  
Remote Monitoring ◽  
Heart Failure Patients ◽  
Long Term Prognosis

scholarly journals 69Impact of remote monitoring on long term prognosis in heart failure patients with atrial fibrillation in a real life cohort - results from all comers registry COMMIT HF Trial

EP Europace ◽  
2018 ◽  
Vol 20 (suppl_1) ◽  
pp. i13-i13
Author(s):  
A Kurek ◽  
M Tajstra ◽  
E Gadula-Gacek ◽  
P Buchta ◽  
L Pyka ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Remote Monitoring ◽  
Real Life ◽  
Heart Failure Patients ◽  
Long Term Prognosis

scholarly journals 219-06: Remote monitoring improves long-term prognosis in heart failure patients with implantable cardioverter-defibrillators - results from all-comers registry

EP Europace ◽  
2016 ◽  
Vol 18 (suppl_1) ◽  
pp. i188-i188
Author(s):  
Anna Kurek ◽  
Mateusz Tajstra ◽  
Elżbieta Gadula-Gacek ◽  
Piotr Buchta ◽  
ŁUkasz Pyka ◽  
...  
Keyword(s):  
Heart Failure ◽  
Remote Monitoring ◽  
Implantable Cardioverter Defibrillators ◽  
Heart Failure Patients ◽  
Long Term Prognosis ◽  
Cardioverter Defibrillators

scholarly journals Effects of Eicosapentaenoic Acid on the Levels of Inflammatory Markers, Cardiac Function and Long-Term Prognosis in Chronic Heart Failure Patients with Dyslipidemia

2014 ◽  
Vol 21 (7) ◽  
pp. 712-729 ◽  
Author(s):  
Keiichi Kohashi ◽  
Akihiro Nakagomi ◽  
Yoshiyuki Saiki ◽  
Taichirou Morisawa ◽  
Munenori Kosugi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cardiac Function ◽  
Eicosapentaenoic Acid ◽  
Inflammatory Markers ◽  
Heart Failure Patients ◽  
Long Term Prognosis

scholarly journals Creatinine Levels at Admission as Predictors of In-Hospital Major Adverse Cardiovascular Events in Acute Heart Failure Patient

2020 ◽  
Vol 6 (1) ◽  
pp. 16-22
Author(s):  
Farida Hanum Margolang ◽  
Refli Hasan ◽  
Abdul Halim Raynaldo ◽  
Harris Hasan ◽  
Ali Nafiah ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Roc Curve ◽  
Cardiovascular Events ◽  
Major Adverse Cardiovascular Events ◽  
High Morbidity ◽  
Roc Curve Analysis ◽  
Heart Failure Patients ◽  
Long Term Prognosis

Background: Acute heart failure is a global health problem with high morbidity and mortality. Short term and long term prognosis of these patients is poor. Therefore, early identification of patients at high risk for major adverse cardiovascular events (MACEs) during hospitalization was needed to improve outcome. Creatinine levels at admission could be used as predictors of major adverse cardiovascular events in acute heart failure patients because creatinine is a simple and routine biomarker of renal function examined in patients with acute heart failure. This study aimed to determine whether creatinine can be used as a predictor of major adverse adverse cardiovascular events in patients with acute heart failure.Methods: This study is a prospective cohort study of 108 acute heart failure patients treated at H. Adam Malik Hospital from July 2018 to January 2019. Creatinine cut-off points were determined using the ROC curve, then bivariate and multivariate analyzes were performed to determine predictors of major adverse cardiovascular events during hospitalization.Results: From 108 study subjects, 24 (22.2%) subjects experienced major adverse cardiovascular events during hospitalization. The subjects who died were 20 people (83.4%), subjects with arrhythmia were 2 people (8.3%), and those who had stroke were 2 people (8.3 %). Through the ROC curve analysis, we found creatinine cut-off values of ≥1.7 mg / dl (AUC 0.899, 95% CI 0.840- 0.957, p <0.05). Creatinine ≥1.7 mg/dl could predict major adverse cardiovascular events with a sensitivity of 87.5% and specificity of 79.5%. Multivariate analysis showed that creatinine ≥1.7 mg / dl was an independent factor to predict MACEs during hospitalization in this study (OR 18,310, p 0.001) as well as creatinine clearance and heart rate.Conclusion: Creatinine levels at admission is an independent predictor for major adverse cardiovascular events during hospitalization in acute heart failure patients.

scholarly journals Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation

2020 ◽  
Vol 27 (2_suppl) ◽  
pp. 27-34
Author(s):  
Stefania Paolillo ◽  
Angela B Scardovi ◽  
Jeness Campodonico
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Prognostic Impact ◽  
Heart Failure Patients ◽  
Cardiovascular Comorbidities ◽  
Long Term Prognosis

Cardiovascular and non-cardiovascular comorbidities are frequently observed in heart failure patients, complicating the therapeutic management and leading to poor prognosis. The prompt recognition of associated comorbid conditions is of great importance to optimize the clinical management, the follow-up, and the treatment of patients affected by chronic heart failure. Anaemia and iron deficiency are commonly reported in all heart failure forms, have a multifactorial aetiology and are responsible for reduced exercise tolerance, impaired quality of life, and poor long-term prognosis. Diabetes mellitus is highly prevalent in heart failure and a poor glycaemic control is associated with worst outcome. Two specific heart failure forms are usually observed in diabetic patients: an ischaemic cardiomyopathy or a typical diabetic cardiomyopathy. The implementation of use of sodium-glucose cotransporter-2 inhibitors will much improve in the near future the long-term prognosis of patients affected by heart failure and diabetes. Among cardiovascular comorbidities, atrial fibrillation is the most common arrhythmic disease of heart failure patients and it is still not clear whether its presence should be considered as a prognostic indicator or as a marker of advanced disease. The aim of the present review was to explore the clinical and prognostic impact of anaemia and iron deficiency, diabetes mellitus, and atrial fibrillation in patients affected by chronic heart failure.

Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients

2016 ◽  
Vol 203 ◽  
pp. 398-406 ◽  
Author(s):  
Michael Behnes ◽  
Thomas Bertsch ◽  
Christel Weiss ◽  
Parviz Ahmad-Nejad ◽  
Ibrahim Akin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Heart Failure Patients ◽  
Galectin 3 ◽  
Long Term Prognosis ◽  
Gremlin 1

scholarly journals What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction

2020 ◽  
Vol 9 (11) ◽  
pp. 3669 ◽  
Author(s):  
René Rettl ◽  
Theresa-Marie Dachs ◽  
Franz Duca ◽  
Christina Binder ◽  
Fabian Dusik ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Real World ◽  
Treatment Options ◽  
National Registry ◽  
Preserved Ejection Fraction ◽  
Eligibility Criteria ◽  
Patients With Heart Failure ◽  
Long Term Prognosis

The PARAGON-HF clinical trial suggested that sacubitril/valsartan may become a treatment option for particular subgroups of patients with heart failure and preserved ejection fraction (HFpEF). However, the proportion of real-world HFpEF patients who are theoretically superimposable with the PARAGON-HF population is yet unknown. The present study was performed to define the proportion of real-world PARAGON-HF-like patients and to describe their clinical characteristics and long-term prognosis in comparison with those who would not meet PARAGON-HF criteria. We systematically applied PARAGON-HF inclusion and exclusion criteria to a total of 427 HFpEF patients who have been participating in a prospective national registry between December 2010 and December 2019. In total, only 170 (39.8%) registry patients were theoretically eligible for PARAGON-HF. Patients not meeting inclusion criteria (41.0%) were less impaired with respect to exercise capacity (median 6-min walk distance: 385 m (IQR: 300–450) versus 323 m (IQR: 240–383); p < 0.001) had lower pulmonary pressures (mean pulmonary artery pressure (mPAP): 31.2 mmHg, standard deviation (SD): ±10.2 versus 32.8 mmHg, SD: ±9.7; p < 0.001) and better outcomes (log-rank: p < 0.001) as compared to the PARAGON-like cohort. However, patients theoretically excluded from the trial (19.2%) were those with most advanced heart failure symptoms (median 6-min walk test: 252 m (IQR: 165–387); p < 0.001), highest pulmonary pressures (mPAP: 38.2 mmHg, SD: ±12.4; p < 0.001) and worst outcome (log-rank: p = 0.037). We demonstrate here that < 40% of real-world HFpEF patients meet eligibility criteria for PARAGON-HF. We conclude that despite reasons for optimism after PARAGON-HF, a large proportion of HFpEF patients will remain without meaningful treatment options.

Sign in / Sign up

Export Citation Format

Share Document